Wat is de prijs voor Exopharm Limited (EX1)

Het prijs van Exopharm Limited (EX1) is $0.00700343

Wat is de marktkapitalisatie voor Exopharm Limited (EX1)

Marktkapitalisatie voorExopharm Limited (EX1) is $637.31K

Exopharm Limited (EX1) Prijs en Marktkapitalisatie

Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.

Prijs voor EX1	Aandeel B	Marktkapitalisatie van B	uitslagen
$60,104.81 $637.31K	NVDA	$5.470T	+858,220,126.04%
$49,088.70 $637.31K	AAPL	$4.467T	+700,924,002.44%
$45,872.38 $637.31K	GOOG	$4.174T	+654,999,089.40%
$40,660.19 $637.31K	MSFT	$3.700T	+580,575,684.25%
$31,366.40 $637.31K	AMZN	$2.854T	+447,872,231.48%

Prijs voor EX1

Aandeel B

Marktkapitalisatie van B

uitslagen

$60,104.81 $637.31K